and noncompetitive inhibition with respect to a K-Ras C-terminal peptide. It also inhibited the in situ farnesylation of cellular Ras proteins in a K-ras transformant (NIH3T3/K-ras) of mouse embryonic fibroblast cell line NIH3T3. TAN-1 8 13 inhibited the proliferation of various human cancer cells, some of which harbor activated ras alleles, with IC50 values of 15~110ng/ml as well as that of NIH3T3 and NIH3T3/K-ras cells with IC50s of 540 and 310ng/ml, respectively. Flow cytometric analysis indicated that TAN-1813 arrests NIH3T3/K-ras cells at both Gl and G2/M phases of the cell cycle. In addition, TAN-1813 was found to induce morphological reversion of NIH3T3/K-ras cells from the transformed phenotype. Antitumor activity of TAN-1813 against human fibrosarcoma HT-1080and NIH3T3/K-ras tumors in nude mice was also verified.
Previous studies have clearly established that small GTPbinding proteins such as Ras, Rho and Rab proteins play crucial roles in regulating cell proliferation and differentiation, organizing actin micro filaments and controlling secretory vesicle transport systems, respectively1~3), and that they exert these distinct functions in specific cellular compartments. Ras proteins, which are representatives of the small GTP-binding protein family, are considered to function as a "molecular switch," which cycle between an active GTP-bound form and an inactive GDP-bound form, receiving signals from receptor-type tyrosine kinases via an adaptor protein (e.g. Grb2) and a GTP/GDP exchange protein (e.g. mSos) complex and transmitting them to downstream effectors such as c-Raf-1, phosphatidylpp. 765 -778 inositol-3-OH kinase and GTPase activating protein (GAP)M'5). Thus, Ras proteins are regarded as one of the key regulators of cell proliferation and differentiation.
Amongthe oncogenes discovered so far, ras genes have been reported to be most frequently activated in human cancer, especially in colon or pancreas cancer6). Such oncogenic activation has been proven to be caused by some point mutations in ras genes, most of which were detected in the domain responsible for the interaction with the guanine nucleotides5). The resultant mutant forms of Ras proteins become refractory to negative regulation such as stimulation of their intrinsic GTPase activity by GAP5), continuously producing active mitogenic signals in such deregulated cells. In other words, the "molecular switch"
Actually, the contribution of the oncogenic Ras proteins to malignant phenotypes of tumor cells has been substantiated in a number of experiments. For instance, selective disruption of an oncogenic allele of K-ras gene using the homologous recombination technique resulted in the loss of anchorage-independent growth and tumorigenicity in nude mice7). In addition, anti-ras ribozymes and antisense oligonucleotides targeted against mutated ras genes have been shown to suppress tumor growth in mice8;9). It is therefore feasible that the blockade of oncogenic ras function leads to loss of malignant phenotypes and will be a successful approach to cancer chemotherapy.
Ras gene products are well conserved evolutionarily from yeasts to mammals, reflecting their pivotal roles in fundamental cellular processes in eukaryotic cells. They are located on the inner surface of plasma membrane in eukaryotic cells, and this is a prerequisite for Ras proteins to be biologically active10). The membrane localization of Ras proteins is achieved by three posttranslational enzymatic modifications1 1^addition of farnesyl isoprenoid to the cysteine residue in the Ras C-terminal "CAAXbox", removal of the tripeptide AAXand carboxymethylation of the newly formed C-terminal cysteine residue. Among these three steps, the first was shown to be essential for the transforming activity of Ras proteinsll 
Materials and Methods
Isolation of Nystatin-resistant Mutant S. cerevisiae FSY1-26C harboring YCp50-RAS2 plasmid was kindly provided by Dr. James R. Broach (Princeton University, U.S.A.). Cells cultivated in 400ml of YPD mediumto a mid-logarithmic phase were harvested, washed once with 400 ml of saline and suspended in 15ml of0.1 m potassium phosphate buffer (pH 8.0). Ethyl methanesulfonate was added to the cell suspension at a final concentration of 20 mg/ml. After incubation at 28°C for 1 hour, cells were washed three times with 40ml of saline, resuspended in 10ml of saline and plated (0.1 ml/plate) on YPD plates (10cm in diameter) containing lO^g/ml nystatin. Colonies were isolated after incubation for 2 days. carried out by the methods described by Malloch18) or described in "Kinrui Kenkyu Ho"19).
Fermentati on
A loopful of mycelia of strain FL-41510 grown on an agar slant was inoculated into a 2-liter flask containing 500 ml of a seed medium consisting of glucose 2%, maltose 3%, soy-bean flour 1.5%, corn steep liquor 1%, Polypepton (Wako Pure Chemical Ind., Japan) 0.5%, yeast extract 0.3% and NaCl 0.3% (pH 6.0) FTase and geranylgeranyltransferase I (GGTaseI) were prepared from rat brain homogenate by the method described previously20) with slight modification. Briefly, 10 whole brains isolated from 5-week-old male Wistar rats were minced with scissors, suspended in 30ml of 50mM Tris/HCl buffer (pH 7.5) containing 1 mMEDTA, 1 mM EGTA, 20^m leupeptin, 0.1 /zm pepstatin A, 10jUg/ml aprotinin and 10 }iu (p-amidinophenyl) methanesulfonyl fluoride (APMSF) and homogenized with a PotterElvehjem homogenizer. Insoluble material was removed by centrifugation at 60,000X# for 70minutes at 4°C, and the supernatant was subjected to ammoniumsulfate fractionation. Proteins precipitated between 30% and 50% saturation were dissolved in 2 ml of 20 mMTris/HCl buffer (pH 7.5) supplemented with 1 mMdithiothreitol, 20mM
ZnCl2, 20/xm leupeptin, 0.1 /im pepstatin A, 10/ig/ml aprotinin and 10 jiu APMSFand then dialyzed overnight against 5 liters of the same buffer. The supernatant (2.5 ml) obtained by centrifugation at 15,000Xg for 10 minutes at 4°C was further subjected to MonoQ column (AmershamPharmacia) chromatography with a linear gradient from 150mMto 500mMNaCl. The active fractions containing FTase or GGTaseI activity were combined separately and stored at -80°C. FTase activity was assayed using an FTase assay kit following the manufacturer's instruction, except that biotin-K-Ras peptide was substituted for biotin-lamin B peptide. GGTase I activity was assayed by the same method as that used for FTase, using 500nMbiotin-Krev-1 peptide and 240 nM 3H-geranylgeranylpyrophosphate (GGPP)
instead of 100nM biotin-K-Ras peptide and 120-nM 3H-farnesylpyrophosphate (FPP).
Cell Lines and Animals
Mouse embryonic fibroblast cell line NIH3T3and its Kras transformant (NIH3T3/K-ras) were generously provided 
Metabolic Labeling ofRas Proteins In Situ
3H-Mevalonolactone labeling of NIH3T3/K-ras cells was performed essentially as described previously22). NIH3T3/ K-ras cells suspended in DMEM/F10 were seeded with 1 X 106 cells per 100-mm dish which was precoated at 37°C for 3 hours with 50 jug/ml bovine plasma fibronectin. Cells were grown at 37°C for 2 days in a humid atmosphere under 5%CO2, and then 3 ml ofDMEMsupplemented with 1% FCS (dialyzed against 0.15m NaCl), 50^M lovastatin and varying concentrations of TAN-1813was added. After incubating for 2 hours, 300^:Ci of 3H-mevalonolactone (33 Ci/mmole) was added to each monolayer culture followed by incubation for an additional 20 hours. The cells in each dish were rinsed three times with 10ml of 50 mMTris/HCl buffer (pH 7.5) containing 0.15 M NaCl and lysed in 700/A of 2-fold diluted Dulbecco's phosphate-buffered saline (DPBS) supplemented with 1% Triton X-100, 5^g/ml leupeptin, 5 jug/ml pepstatin A, 5 jug/ml aprotinin and 10 jiu APMSF(Lysis Buffer). After standing on ice for 5 minutes, the lysates were centrifuged at 12,000Xg for 30 seconds, and supernatant containing 700 jig of protein was dissolved in 10ji\ of DPBS had previously been added. After culturing for 3 days at 37°C in a humid atmosphere under 5% CO2, 25ji\ of MTT solution (5mg/ml) was added, and the mixture was incubated for an additional 5 hours under the sameconditions. The reaction was then stopped by adding 0.1 ml of 10% SDS/0.01 N HC1 solution. After incubating overnight, the absorbance at 620nm was measured, and the growth-inhibitory activity was calculated.
Flow Cytometric Analysis
The effect of TAN-1813 on the cell cycle progression of NIH3T3/K-ras cells was evaluated. NIH3T3/K-ras cells suspended in DMEM/F10 were plated at a density of 3X 105 cells per 100-mm dish and synchronized in S phase by 24 -hour incubation in the presence of 1 jiu aphidicolin. Cells were then washed three times with 10 ml of prewarmed DMEM/F10 to release them from the S phase block and were further cultured in 10ml of DMEM/F10 to allow them to progress into G2 and M phases. Immediately or several hours after the release, TAN-1813was added to the culture medium at a final concentration of 5 /ig/ml to determine the growth-inhibitory effect in different phases of the cell cycle. Twenty-nine hours after the release, cells were harvested, fixed, stained with 50 /ig/ml of propidium iodide and analyzed using a FACScanFlow Cytometer (Becton Dickinson, U.S.A.).
Assay of Antitumor Activity In Vivo A human fibrosarcoma HT-1080 xenograft model was established by subcutaneous inoculation of the cells (3 X 106 cells/mouse) into adult male BALB/cnu/nu mice. Eleven days after tumor inoculation, TAN-1813 suspended in 0.5% methylcellulose in saline was administered daily cerevisiae was isolated and, as expected, the mutant strain TYC4 showed marked sensitivity to various cytotoxic compounds (Table 1) . Furthermore, high permeability of plasma membraneof the nystatin-resistant strain was also supported by the observation that phloxine B pigment was taken up by the strain TYC4but not by the wild-type strain FSY1-26C (data not shown). As the next step, another nystatin-resistant strain TYC8which grows depending on non-farnesylated Ras2Ser319 proteins16) was constructed as described in Materials and Methods, and, on the course of the screening program, we found a plant endophyte fungus, FL-41510, to produce an active principle which inhibited the growth of TYC4preferentially.
Taxonomy of the Producing Organism
Strain FL-41510 was isolated as an endophyte from a root of Erigeron annuus collected in Fukushima Prefecture, Japan. Cultural and morphological characteristics of strain FL-41510 were as follows: colonies were fast-growing, reaching 33-35mm in diameter in 2 weeks at 24°C on potato-dextrose agar, producing raised wooly aerial mycelium with pale gray to whitish gray color with a slightly irregular periphery. Soluble pigment was not produced. After 3 weeks or more, many dark brownish pycnidia were observed in the agar medium. Aerial hyphae were septate, smooth to rough surface. Pycnidia were mostly globose to ellipsoidal shape, 150-200jum in diameter, having one ostiole ( Fig. 2A) . Abundant conidia were produced in a pycnidium. Conidia were single-celled, smooth, hyaline, ellipsoidal to ovoid, 3~5X l.5-~2.jUm (Fig.   2B ). The gross taxonomical characteristics of strain FL-415 10 described above clearly indicate that it belongs to the genus Phomal^21). The strain has been deposited as Phoma 
Fermentation
A typical time course of the production of TAN-1813 on the 40-ml cultivation scale is shown in Fig. 3 . While the growth of strain FL-41510 reached almost the maximum level as early as after 3 days of cultivation, the production Fig. 4B ) with respect to biotin-K-Ras peptide (Ki=4l /im). The kinetics of the GGTase I inhibition, by TAN-1813 was tested in reaction mixtures containing 500 nMbiotin-Krev-1 peptide and varying concentrations of 3H-GGPPLineweaver-Burk plots indicated that, in contrast to the FTase inhibition, TAN-1813was noncompetitive (Ki= 166 ijm) with respect to GGPP (Fig. 5) .
Inhibition of Cell Proliferation
TAN-1813 showed growth-inhibitory activity against cultured cells including a wide variety of human carcinoma cells (Table 2 ). Its inhibitory activity was comparable against NIH3T3 and its K-ras transformant cells but was about 10-fold more potent against all human tumor cells than against the normal human flbroblast MRC-9 (Table 2) . However, there was no difference in the sensitivity to TAN-1813 between the cells with the normal ras allele and those with the oncogenic ras allele such as A549, MDA-MB-23 1, MIAPaCa-2, SW480, HepG2 and HT-1080 in a monolayer culture ( Table 2) . Assays of growth-inhibitory activity of TAN-1813 were carried out as described in Materials and Methods. The cell lines with an asterisk (*) have been reported to harbor oncogenic ras mutations.
Effect on the Cell Cycle Progression of NIH3T3/K-ras Cells
To examine the point in the cell cycle where TAN-1813 acts, we carried out flow cytometric analyses using NIH3T3/K-ras cells. NIH3T3/K-ras cells synchronized in early S phase by aphidicolin treatment (Fig. 8A-2) were washed with drug-free medium. After release from the S phase block, the cells progressed into G2/M and Gl phases 5 and 10 hours later, respectively (Fig. 8A-3 and -4), Under these experimental conditions, TAN-1 813 was added to the medium immediately and 5 and 10 hours after the release in order to examine the effect against cells in S, G2/Mand Gl phases of the cell cycle, respectively. Irrespective of the cell cycle state at the beginning of TAN-1813 treatment, NIH3T3/K-ras cells were arrested at both Gl and G2/M phases ( Fig. 8B-1, -2 and -3 ).
Antitumor Activity In Vivo
Antitumor activity of TAN-1813was evaluated in mice implanted with two types of oncogenic ras-harboring cells. Intraperitoneal administration at doses of 6.3 and 25 mg/kg reduced the growth of HT-1080 tumor cells, which have been reported to harbor an oncogenic mutation (Q61K) in the N-ras gene29), without causing marked body weight loss (Table 3) . Subcutaneous administration at higher doses (30~100mg/kg) was also effective against HT-1080 and NIH3T3/K-ras tumor growth (Table 3 and 4, respectively).
In addition, antitumor activity was also observed in nude mice bearing AsPC-1humanpancreas carcinoma (data not shown). Minimum lethal doses of TAN-1813 were 200-400mg/kg or 50mg/kg when administered subcutaneously or intraperitoneally, respectively (ICR male mice, 6-week-old).
Discussion
Since the frequent incidence of the; gain-of-function (A) Cells were synchronized in the early S phase by aphidicolin and released in drug-free medium as described in Materials and Methods. At appropriate time points, cells were harvested, stained and analyzed by flow cytometry.
(1), asynchronous culture; (2), aphidicolin synchronized culture; (3), 5-hour after release; (4), 1 0-hour after release.
(B) Cells were synchronized as in (A) and released in drug-free medium. Immediately (1), 5 hours (2) or 10 hours later (3), TAN-1813 (final 5/ig/ml) was added to the medium, and 29hours after release from the S phase block, cells were analyzed as in (A). mutations in ras genes was reported with humantumor specimens6), many researchers have strived for "anti-Ras drugs" based on the activity to revert the morphologically transformed phenotype to the normal one, aiming at pharmacological manipulations which suppress the activity of oncogenic Ras proteins. Such efforts, however, have not been fruitful probably because such a screening method was not directly targeted against Ras proteins. Indeed, most, if not all, of the compounds discovered through this approach don't seem to be specific against Ras proteins. However, the recent finding that the farnesylation of oncogenic Ras is essential for its cell transforming activity unique structure (Fig. 1) , and FTase inhibition is supposed to be due to this moiety because this inhibitor was competitive (Ki=29^m) with FPP and noncompetitive with Ras C-terminal undecapeptide (Fig. 4) . This kinetic data also suggested that it might also be competitive with GGPP, but the detailed kinetic study revealed that it was noncompetitive (Ki=166jjm) with GGPP (Fig. 5) . It is therefore suggested that TAN-1813 inhibits FTase in a distinct manner from that in which it inhibits GGTaseI, and its FTase-inhibitory activity could fluctuate in response to the changes of the cellular FPP concentration. Furthermore, the 3H-mevalonolactone labeling experiment demonstrated that in situ prenylation of the small G proteins other than Ras proteins (e.g. Rho and Rab proteins) appeared less affected by TAN-1813 treatment compared to the Rasfarnesylation ( Fig. 6A and B) . We have not yet explored the reason for the apparent difference in the effect of TAN-1813 between the cell-free assay and the cellular assay, but it is possible that TAN-1813 might not inhibit GGTase II activity responsible for geranylgeranylation of Rab proteins and the residual bands appearing between 18.5 kDa and 27.5kDa in Fig. 6A might correspond to this enzyme activity. Another straightforward possibility is that FTase might be more sensitive to this compound than is GGTase in the normal cellular compartments. In any case, some small G proteins other than Ras proteins seem to be insensitive to the inhibitory effect of TAN-1813, but whether the residual activity is sufficient to support the functions ofRho and Rab proteins is not clear. TAN-1 8 13 showed equipotent inhibitory activity against the proliferation of NIH3T3 cells and its K-ras transformed cells (Table 2) , although the recently developed FTasespeciflc CAAX-based inhibitors22'49) have been reported to specifically inhibit the growth of ras-transformed cells. In spite of the nonselectivity observed in the growth-inhibition experiment, TAN-1813 was able to induce the reversion of NIH3T3/K-ras cells from the transformed morphology to the normal one (Fig. 7) . This activity of TAN-1813 seems to be manifested through the inhibition of Rasfarnesylation, leading to the abrogation of Ras function, since the FTase-specific inhibitors have been reported to AUG. 2000 have this activity22' 49' 50). However, the involvement of inhibition of Rho function cannot be ruled out because Rho proteins play important roles in regulation of actin filament organization1) which is critical for cell shape determination.
It is quite difficult to determine the primary contributing factor for this activity as the functions of Rho proteins have been reported to be controlled by Ras proteins1). However, taking into account the fact that this activity was observed at TAN-1813 concentrations of 1 /ig/ml, the concentration range which abolished the Ras-farnesylation completely but the geranylgeranylation of other small G proteins incompletely in the cells, it is likely that inactivation of Ras proteins was primarily responsible for this morphological reversion. Addition of TAN-1813 caused NIH3T3/K-ras cells to cease their cell cycle progression at both Gl and G2/M phases, which excludes the possibility that TAN-1813 directly inhibits DNAsynthesis and arrests cells at S phase. This is partially inconsistent with the previous observation that lovastatin and simvastatin, which are HMG-CoA reductase inhibitors and were reported to inhibit Rasfarnesylation by reducing the FPP content in the cells, pre-dominantly inhibited Gl to S phase transition in T24 bladder carcinoma51) and MIAPaCa-2 pancreas carcinoma52), respectively. It is also reported that the growth-inhibitory activity of lovastatin is not due to the inactivation of Ras53) and that Ras function is also required for G2 to Mtransition in addition to Gl to S transition54). Therefore, the exact roles of Ras proteins in each step of the cell cycle have not been elucidated yet, and clarification of the molecular target(s) of TAN-1813 may lead to a better understanding of Ras functions in cell cycle regulation. Although the potency of TAN-1813 to inhibit FTase in the cell-free enzyme assay is rather low (IC50=23 /ig/ml), inhibition of cellular Ras-farnesylation in and growth of NIH3T3/K-ras cells could be detected at about 10-and 100-fold lower concentrations, respectively ( Fig. 6 and Table 2 ). This discrepancy cannot be explained clearly as yet, but, taking into consideration that TAN-18 13 treatment time was an hour for the cell-free FTase assay, 22 hours for 3H-mevalonolactone labeling experiment and 3 days for growth inhibition experiment, it is possible that the inhibitory activity becomes stronger as the treatment period becomes longer. Indeed, the CAAX-based FTase inhibitors have been shown to require a long incubation time to elicit an apparent inhibitory effect22'49). Alternatively, since TAN-1813 competes with FPP (Fig. 4) 
